The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Phase 3 study on Perifosine to continue

coloCan
coloCan CSN Member Posts: 1,944 Member
edited September 2011 in Colorectal Cancer #1
medicalnewstoday.com/releases/233688.php

which is xeloda plus this.....for people for whom all else seems to be ineffective....
Like Care

Comments

  • Buckwirth
    Buckwirth CSN Member Posts: 1,258 Member
    #2
    Perifosine
    Is biotherapy, similar to Erbitux. There is nothing that I can find in the literature saying it is KRAS dependent, so this trial could be of interest to those with mutated KRAS, as well as to those with wild KRAS but for whom the EFGR inhibitors are no longer effective.

    Keep an eye on this one. The Phase 2 trial was promising, it is fast tracked by the FDA, and could become generally available in the next two to five years.
    Like Care
  • coloCan
    coloCan CSN Member Posts: 1,944 Member
    #3
    Buckwirth said:

    Perifosine
    Is biotherapy, similar to Erbitux. There is nothing that I can find in the literature saying it is KRAS dependent, so this trial could be of interest to those with mutated KRAS, as well as to those with wild KRAS but for whom the EFGR inhibitors are no longer effective.

    Keep an eye on this one. The Phase 2 trial was promising, it is fast tracked by the FDA, and could become generally available in the next two to five years.

    As per article:
    "......Patients must have failed available therapy including 5-fluorouracil (5-FU),oxaliplatin (Eloxatin),irinotecan,bevacizumab (Avastin) and if KRAS wild-type,failed therapy with prior cetuximab (Erbitux) and/or panitumumab (Vectibix)......"

    Not much left out.......
    Like Care

Discussion Boards